Inhibition of weak-affinity epitope-IgE interactions prevents mast cell degranulation

Michael W. Handlogten, Tanyel Kiziltepe, Ana P. Serezani, Mark Kaplan, Basar Bilgicer

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Development of specific inhibitors of allergy has had limited success, in part, owing to a lack of experimental models that reflect the complexity of allergen-IgE interactions. We designed a heterotetravalent allergen (HtTA) system, which reflects epitope heterogeneity, polyclonal response and number of immunodominant epitopes observed in natural allergens, thereby providing a physiologically relevant experimental model to study mast cell degranulation. The HtTA design revealed the importance of weak-affinity epitopes in allergy, particularly when presented with high-affinity epitopes. The effect of selective inhibition of weak-affinity epitope-IgE interactions was investigated with heterobivalent inhibitors (HBIs) designed to simultaneously target the antigen- and nucleotide-binding sites on the IgE Fab. HBI demonstrated enhanced avidity for the target IgE and was a potent inhibitor of degranulation in vitro and in vivo. These results demonstrate that partial inhibition of allergen-IgE interactions was sufficient to prevent mast cell degranulation, thus establishing the therapeutic potential of the HBI design.

Original languageEnglish
Pages (from-to)789-795
Number of pages7
JournalNature Chemical Biology
Volume9
Issue number12
DOIs
StatePublished - Dec 2013

Fingerprint

Cell Degranulation
Mast Cells
Allergens
Immunoglobulin E
Epitopes
Hypersensitivity
Theoretical Models
Immunodominant Epitopes
Nucleotides
Binding Sites
Antigens

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

Inhibition of weak-affinity epitope-IgE interactions prevents mast cell degranulation. / Handlogten, Michael W.; Kiziltepe, Tanyel; Serezani, Ana P.; Kaplan, Mark; Bilgicer, Basar.

In: Nature Chemical Biology, Vol. 9, No. 12, 12.2013, p. 789-795.

Research output: Contribution to journalArticle

Handlogten, Michael W. ; Kiziltepe, Tanyel ; Serezani, Ana P. ; Kaplan, Mark ; Bilgicer, Basar. / Inhibition of weak-affinity epitope-IgE interactions prevents mast cell degranulation. In: Nature Chemical Biology. 2013 ; Vol. 9, No. 12. pp. 789-795.
@article{0cd641a591754241b1c67a072e6f264e,
title = "Inhibition of weak-affinity epitope-IgE interactions prevents mast cell degranulation",
abstract = "Development of specific inhibitors of allergy has had limited success, in part, owing to a lack of experimental models that reflect the complexity of allergen-IgE interactions. We designed a heterotetravalent allergen (HtTA) system, which reflects epitope heterogeneity, polyclonal response and number of immunodominant epitopes observed in natural allergens, thereby providing a physiologically relevant experimental model to study mast cell degranulation. The HtTA design revealed the importance of weak-affinity epitopes in allergy, particularly when presented with high-affinity epitopes. The effect of selective inhibition of weak-affinity epitope-IgE interactions was investigated with heterobivalent inhibitors (HBIs) designed to simultaneously target the antigen- and nucleotide-binding sites on the IgE Fab. HBI demonstrated enhanced avidity for the target IgE and was a potent inhibitor of degranulation in vitro and in vivo. These results demonstrate that partial inhibition of allergen-IgE interactions was sufficient to prevent mast cell degranulation, thus establishing the therapeutic potential of the HBI design.",
author = "Handlogten, {Michael W.} and Tanyel Kiziltepe and Serezani, {Ana P.} and Mark Kaplan and Basar Bilgicer",
year = "2013",
month = "12",
doi = "10.1038/nchembio.1358",
language = "English",
volume = "9",
pages = "789--795",
journal = "Nature Chemical Biology",
issn = "1552-4450",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Inhibition of weak-affinity epitope-IgE interactions prevents mast cell degranulation

AU - Handlogten, Michael W.

AU - Kiziltepe, Tanyel

AU - Serezani, Ana P.

AU - Kaplan, Mark

AU - Bilgicer, Basar

PY - 2013/12

Y1 - 2013/12

N2 - Development of specific inhibitors of allergy has had limited success, in part, owing to a lack of experimental models that reflect the complexity of allergen-IgE interactions. We designed a heterotetravalent allergen (HtTA) system, which reflects epitope heterogeneity, polyclonal response and number of immunodominant epitopes observed in natural allergens, thereby providing a physiologically relevant experimental model to study mast cell degranulation. The HtTA design revealed the importance of weak-affinity epitopes in allergy, particularly when presented with high-affinity epitopes. The effect of selective inhibition of weak-affinity epitope-IgE interactions was investigated with heterobivalent inhibitors (HBIs) designed to simultaneously target the antigen- and nucleotide-binding sites on the IgE Fab. HBI demonstrated enhanced avidity for the target IgE and was a potent inhibitor of degranulation in vitro and in vivo. These results demonstrate that partial inhibition of allergen-IgE interactions was sufficient to prevent mast cell degranulation, thus establishing the therapeutic potential of the HBI design.

AB - Development of specific inhibitors of allergy has had limited success, in part, owing to a lack of experimental models that reflect the complexity of allergen-IgE interactions. We designed a heterotetravalent allergen (HtTA) system, which reflects epitope heterogeneity, polyclonal response and number of immunodominant epitopes observed in natural allergens, thereby providing a physiologically relevant experimental model to study mast cell degranulation. The HtTA design revealed the importance of weak-affinity epitopes in allergy, particularly when presented with high-affinity epitopes. The effect of selective inhibition of weak-affinity epitope-IgE interactions was investigated with heterobivalent inhibitors (HBIs) designed to simultaneously target the antigen- and nucleotide-binding sites on the IgE Fab. HBI demonstrated enhanced avidity for the target IgE and was a potent inhibitor of degranulation in vitro and in vivo. These results demonstrate that partial inhibition of allergen-IgE interactions was sufficient to prevent mast cell degranulation, thus establishing the therapeutic potential of the HBI design.

UR - http://www.scopus.com/inward/record.url?scp=84887943069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887943069&partnerID=8YFLogxK

U2 - 10.1038/nchembio.1358

DO - 10.1038/nchembio.1358

M3 - Article

C2 - 24096304

AN - SCOPUS:84887943069

VL - 9

SP - 789

EP - 795

JO - Nature Chemical Biology

JF - Nature Chemical Biology

SN - 1552-4450

IS - 12

ER -